Study guide
31.1 Recurrent Aphthous Stomatitis
Overseas Registration Examination ORE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy
1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits
2 Chapter 2: Anatomy of the Head and Neck
2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection
3 Chapter 3: Dental Anatomy, Morphology and Occlusion
3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships
4 Chapter 4: Genetics, Embryology and Odontogenesis
4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies
5 Chapter 5: Oral Biology and Salivary Physiology
5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics
6 Chapter 6: Physiology of the Major Body Systems
6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System
7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing
7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk
8 Chapter 8: Oral Microbiology and Biofilm Ecology
8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control
9 Chapter 9: Immunology Relevant to Oral Disease
9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations
10 Chapter 10: General Pathology and Neoplasia
10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma
11 Chapter 11: Statistics and Research Methods
11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance
12 Chapter 12: Human Disease: Cardiovascular and Respiratory
12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies
13 Chapter 13: Human Disease: Endocrine, Haematological and Renal
13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis
14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological
14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis
15 Chapter 15: Oral Aspects of Human Disease
15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis
16 Chapter 16: Infection Prevention and Control
16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses
17 Chapter 17: Dental Materials
17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers
18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care
18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health
19 Chapter 19: Patient Assessment and Diagnosis
19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis
20 Chapter 20: Treatment Planning and Risk-Based Care
20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning
21 Chapter 21: Cariology and Caries Risk Assessment
21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment
22 Chapter 22: Operative Dentistry and Minimal Intervention
22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry
23 Chapter 23: Endodontics
23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture
24 Chapter 24: Periodontology
24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care
25 Chapter 25: Fixed Prosthodontics
25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements
26 Chapter 26: Removable Prosthodontics
26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration
27 Chapter 27: Paediatric Dentistry
27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits
28 Chapter 28: Dental Traumatology
28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications
29 Chapter 29: Orthodontics
29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention
30 Chapter 30: Oral Surgery
30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread
31 Chapter 31: Oral Medicine
31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy
32 Chapter 32: Oral Pathology
32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms
33 Chapter 33: Therapeutics and Prescribing
33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics
34 Chapter 34: Medical Emergencies in Dental Practice
34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation
35 Chapter 35: Dental Radiology and Radiation Protection
35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017
36 Chapter 36: Special Care Dentistry and Conscious Sedation
36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral
37 Chapter 37: Dental Public Health
37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning
38 Chapter 38: Communication and Interpersonal Skills
38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team
39 Chapter 39: Consent and Capacity
39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure
40 Chapter 40: Clinical Professionalism and the GDC
40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle
41 Chapter 41: Health and Safety Law in Dental Practice
41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps
42 Chapter 42: Self-Management and Professional Development
42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management
31.1 Recurrent Aphthous Stomatitis
Key Takeaways Explain This Topic AI
Minor aphthae measure under 10 mm, occur on non-keratinised mucosa and heal within 10 to 14 days without scarring.
Major aphthae exceed 10 mm, favour the posterior mouth and oropharynx, persist for weeks to months and heal with scarring.
Herpetiform ulceration produces crops of 1 to 2 mm pinpoint ulcers that may coalesce, healing in 10 to 14 days.
Haematinic deficiency of iron, folate or vitamin B12 is found in about 5% to 10% of patients and warrants blood screening.
Any single ulcer persisting beyond three weeks must be treated as possible malignancy and referred urgently, not redressed.
Last updated: September 2026
Recurrent Aphthous Stomatitis (RAS)
Recurrent aphthous stomatitis (RAS) , or aphthae, is the most common non-traumatic ulcerative disease of the oral mucosa, affecting approximately 20% of the global population. It is characterized by recurrent, painful, well-demarcated ovoid necrotising ulcers that develop in childhood or adolescence and recur at variable intervals.
Etiopathogenesis
The precise primary trigger remains idiopathic, but the disease represents a cell-mediated immune dysregulation (type IV hypersensitivity response). Cytotoxic CD8+ T-lymphocytes and tumour necrosis factor-alpha (TNF-α) mediate focal epithelial necrosis and basement membrane destruction, exacerbated by local microtrauma, emotional stress, hormonal fluctuations, and genetic susceptibility (HLA-B51, HLA-Cw7).
Clinical Classification
RAS is classified into three clinically distinct variants based on ulcer size, number, distribution, healing duration, and scarring potential: Recurrent Aphthous Stomatitis (RAS)
- │
- ┌──────────────────────────────────┼──────────────────────────────────┐
- ▼ ▼ ▼
- Minor Aphthae Major Aphthae Herpetiform Ulceration
- 80% of all cases • 10% of all cases • 5–10% of cases
- <10 mm (typically 2–5 mm) • >10 mm (often 1–3 cm) • 1–2 mm pinpoint crops
- 1–5 ulcers per crop • 1–3 ulcers per crop • 10–100 ulcers coalescing
- Non-keratinised mucosa only • Keratinised + non-keratinised • Non-keratinised + keratinised
- Heals in 10–14 days • Persists weeks to months • Heals in 10–14 days
- NO scarring • HEALS WITH SCARRING • Scarring unusual
Minor Aphthous Ulcers (Mikulicz's Aphthae):
Account for approximately 80% of all RAS presentations.
Morphology: Round to ovoid, shallow ulcers with a grey-yellow necrotic pseudomembranous floor surrounded by an intense, raised erythematous halo.
Size & Number: Measuring <10 mm in diameter (typically 2–5 mm), occurring in crops of 1 to 5 ulcers.
Anatomical Distribution: Confined strictly to non-keratinised mobile oral mucosa (labial mucosa, buccal mucosa, ventral tongue, floor of the mouth, and unattached sulcal mucosa). They notably spare the hard palate, attached gingiva, and dorsal tongue.
Natural History: Painful during the initial 3–4 days; heal spontaneously within 10 to 14 days without tissue scarring .
Major Aphthous Ulcers (Sutton's Disease / Periadenitis Mucosa Necrotica Recurrens):
Account for approximately 10% of cases.
Morphology: Deep, punched-out, crateriform ulcerations with rolled, indurated, raised margins and severe background edema.
Size & Number: Measuring >10 mm in diameter (frequently 10–30 mm), presenting as 1 to 3 simultaneous lesions.
Anatomical Distribution: Involves both non-keratinised and keratinised mucosa, exhibiting a distinct predilection for the posterior oral cavity and oropharynx (soft palate, tonsillar pillars, palatopharyngeal folds, and dorsum of the tongue).
Natural History: Highly debilitating; lesions persist for weeks to months (typically 3–6 weeks or longer). They heal with permanent fibrous scarring and mucosal architecture distortion .
Critical Diagnostic Milestone: Because of their large size, raised indurated borders, and chronicity, major aphthae closely mimic Oral Squamous Cell Carcinoma (OSCC) or deep fungal/mycobacterial infections. Any indurated solitary ulcer persisting >3 weeks requires an urgent suspected cancer referral for incisional biopsy.
Herpetiform Ulceration:
Accounts for 5% to 10% of cases.
Morphology: Crops of multiple tiny, pinpoint, shallow ulcerations measuring 1 to 2 mm across that rapidly coalesce into irregular, ragged, painful erosive maps.
Size & Number: Characterized by extensive crops of 10 to 100 ulcers simultaneously.
Anatomical Distribution: Can affect any mucosal surface, but exhibits a predilection for the ventral tongue, lateral borders of the tongue, and floor of the mouth.
Natural History: Heal within 10 to 14 days; scarring is generally absent unless confluence produces deep secondary necrosis.
Pathology Distinction: Despite the name "herpetiform", this condition has no viral aetiology (it is entirely unrelated to Herpes Simplex Virus; cultures and PCR for HSV-1 are negative, and there is no preceding vesicular stage).
- Clinical Parameter Minor Aphthae Major Aphthae (Sutton's) Herpetiform Ulcers
- Proportion of Cases ~80% ~10% 5–10%
- Ulcer Diameter <10 mm (typically 2–5 mm) >10 mm (often 10–30 mm) 1–2 mm (pinpoint)
- Number per Episode 1–5 1–3 10–100 (crops)
Mucosal Site Non-keratinised mucosa only Keratinised and non-keratinised (palatopharyngeal) Non-keratinised and keratinised (ventral tongue)
- Duration of Episode 10–14 days Weeks to months 10–14 days
- Healing Sequelae No scarring Heals with scarring Rare scarring
- Aetiology T-cell mediated T-cell mediated (severe) T-cell mediated (no HSV involvement)
- Systemic Associations & Screening Protocol
While the vast majority of RAS cases are idiopathic, secondary aphthous-like ulceration can represent the initial sign of severe underlying haematological, gastrointestinal, or rheumatological disease. In the UK, initial screening in primary dental care or secondary oral medicine clinics requires systematic laboratory investigation: Systemic Investigation of RAS
- │
- ┌──────────────────┬──────────────────────┴──────────────────────┬──────────────────┐
- ▼ ▼ ▼ ▼
- Haematinic Profile Coeliac Serology IBD Evaluation Behçet's
- Serum Ferritin • Anti-tTG IgA • Faecal Calprotectin• Orogenital
- Serum Folate • Total Serum IgA (exclude IgA deficiency) • Colonoscopy / MRE Ulceration
- Serum B12 • Duodenal biopsy gold standard • Orofacial Granuloma• Uveitis
- Full Blood Count • Snail-track ulcers • Pathergy
Haematinic Deficiencies:
Deficiencies in serum ferritin (iron stores) , vitamin B12 (cobalamin) , and red cell / serum folate occur in 15–20% of patients with severe recurrent aphthae. Correction of the specific nutritional deficit produces complete remission or dramatic reduction in ulcer frequency in over 70% of deficient patients.
Complete Blood Count (CBC/FBC) assesses for microcytic hypochromic anaemia (iron deficiency) or macrocytic megaloblastic anaemia (B12/folate deficiency).
Coeliac Disease (Gluten-Sensitive Enteropathy):
An autoimmune enteropathy induced by dietary gluten ingestion in genetically susceptible individuals (HLA-DQ2/DQ8).
Up to 5% of patients with intractable aphthae have silent coeliac disease. It impairs intestinal villous absorption, precipitating secondary iron, folate, and calcium deficiencies.
Screening: Serum anti-tissue transglutaminase IgA (anti-tTG IgA) antibodies alongside total serum IgA (to rule out selective IgA deficiency, which gives false-negative anti-tTG results; if IgA deficient, IgG-based anti-DGP or anti-tTG IgG must be assayed). Definitive diagnosis: small bowel / duodenal endoscopic biopsy showing subtotal villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis.
Inflammatory Bowel Disease (IBD):
Crohn's Disease: Transmural granulomatous inflammation of any GI tract segment. Intraoral manifestations frequently precede intestinal symptoms: deep, linear, "snail-track" or fissured ulcers in the buccal sulci with hyperplastic folded margins, diffuse lip and cheek swelling ( orofacial granulomatosis / OFG ), "cobblestone" mucosal architecture from submucosal lymphoedema, and polypoid mucosal tags.
Ulcerative Colitis: Mucosal inflammation confined to the colon and rectum; oral manifestations include aphthae and pyostomatitis vegetans (multiple tiny pustules and vegetating friable mucosal folds that rupture into "snail-track" ulcerations).
Behçet's Syndrome (Behçet's Disease):
A chronic, relapsing, multisystem systemic vasculitis of unknown aetiology characterized by occlusive necrotising endarteritis of small and large vessels.
International Diagnostic Criteria: Recurrent oral aphthae (observed by clinician or reliably reported at least 3 times in a 12-month period) plus at least two of the following:
Recurrent genital ulceration (painful, scarring scrotal or vulval ulcers).
Ocular inflammation (anterior or posterior uveitis, hypopyon, retinal vasculitis causing visual loss).
Cutaneous lesions (erythema nodosum, pseudofolliculitis, acneiform nodules).
Positive Pathergy Test: An exaggerated sterile erythematous papule or pustule developing 24–48 hours following oblique skin puncture with a sterile 20-gauge needle.
Other Rare Associations:
Cyclic Neutropenia: Autosomal dominant ELANE mutation; regular 21-day cycles of severe peripheral neutropenia (<0.5 × 10⁹/L) presenting with recurrent severe aphthous ulceration, fever, cervical lymphadenopathy, and aggressive periodontal bone loss.
MAGIC Syndrome: Mouth And Genital ulcers with Inflamed Cartilage (features of both Behçet's and relapsing polychondritis).
PFAPA Syndrome: Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis in young children.
Clinical Management Ladder in the UK
Management aims to alleviate pain, accelerate re-epithelialisation, reduce ulcer duration, and prolong disease-free remission:
First-Line (Topical Symptomatic & Barrier Therapy):
Analgesic / Anti-inflammatory mouthwashes: Benzydamine hydrochloride 0.15% oral rinse or spray (Difflam) every 2–3 hours before meals to reduce pain.
Barrier agents: Carmellose sodium paste (Orabase) applied over lesions to shield exposed nerve endings from salivary enzymes and mechanical friction.
Antimicrobial rinses: Chlorhexidine gluconate 0.2% mouthwash (10 mL bd) or hydrogen peroxide 1.5% mouthwash to prevent secondary bacterial infection and hasten healing.
Second-Line (Topical Corticosteroids):
Hydrocortisone Oromucosal Pellets (2.5 mg): 1 pellet dissolved in the mouth in close proximity to the ulcer 4 times daily (qds). Best initiated during the prodromal stinging phase.
Betamethasone Soluble Tablets (0.5 mg): 1 tablet dissolved in 10 mL of water, used as an intensive mouthwash for 2–3 minutes and then spat out, 2 to 4 times daily. (Avoid swallowing to minimise systemic absorption and hypothalamic-pituitary-adrenal [HPA] axis suppression).
Beclometasone Dipropionate Inhaler (50–100 μg/actuation): 1–2 sprays targeted directly onto localized lesions twice daily.
Clobetasol Propionate Ointment (0.05%) mixed 1:1 with Orabase: Applied topically tid for recalcitrant major aphthae.
Third-Line (Secondary Care Specialist Systemic Immunomodulation):
Reserved for debilitating major aphthae or Behçet's disease managed by Oral Medicine consultants: short courses of systemic prednisolone (30–40 mg/day tapered over 2–3 weeks), colchicine (500 μg bd–tid), dapsone , thalidomide (strictly controlled due to teratogenicity / phocomelia and peripheral neuropathy), or anti-TNF-α biologic therapies ( infliximab , adalimumab ).
Sections you finish are checked off in the contents.
- Up Next
- 31.2 Oral Candidiasis
- Continue learning